Nambudiri Vinod E, Keating Nancy L
a Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
b Department of Health Care Policy, Harvard Medical School, Boston, MA 02115, USA.
Expert Rev Endocrinol Metab. 2010 Jul;5(4):531-537. doi: 10.1586/eem.10.35.
Androgen-deprivation therapy is frequently used to treat metastatic prostate cancer and is increasingly used to treat local and regional prostate cancer. Androgen deprivation has been shown to increase central obesity and insulin resistance, and it can alter serum lipid profiles. Recent data suggest that androgen-deprivation therapy is also associated with incident diabetes and cardiovascular disease and cardiac-related mortality. Patients and physicians making decisions regarding the use of androgen-deprivation therapy should weigh the benefits and possible risks, particularly when androgen-deprivation therapy is being used for indications where benefits have not been clearly defined. They may also want to consider monitoring for possible side effects related to cardiovascular and metabolic outcomes.
雄激素剥夺疗法常用于治疗转移性前列腺癌，并且越来越多地用于治疗局部和区域性前列腺癌。雄激素剥夺已被证明会增加中心性肥胖和胰岛素抵抗，还会改变血清脂质谱。最近的数据表明，雄激素剥夺疗法还与新发糖尿病、心血管疾病及心脏相关死亡率有关。决定是否使用雄激素剥夺疗法的患者和医生应权衡其益处和潜在风险，尤其是当雄激素剥夺疗法用于益处尚未明确界定的适应症时。他们可能还需要考虑监测与心血管和代谢结果相关的潜在副作用。
